H.C. Wainwright analyst Robert Burns lowered the firm’s price target on ADC Therapeutics (ADCT) to $7 from $8 and keeps a Buy rating on the shares. The firm reduced the price target after factoring in the private placement financing.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADCT:
- ADC Therapeutics Announces $60M Private Placement
- ADC Therapeutics sees Q3 sales of zynlonta about $15.8M
- ADC Therapeutics announces $60M private placement
- Positive Buy Rating for ADC Therapeutics Amid Promising Clinical Trials and Strong Valuation
- ADC Therapeutics Updates Strategic Focus on ZYNLONTA